Neoantigen × AI
Daily research signal
№45Brief

Moderna Phase 3 Turns Neoantigen Vaccines Into Commercial Category

Today's throughline is optimization.

Moderna's intismeran–Keytruda Phase 3 data has turned personalized neoantigen vaccines into a market-moving commercial category, while the remaining items probe the design levers that will separate winners: vaccine timing relative to surgery in pancreatic cancer, antigen presentation density, and whether complex ML actually outperforms simple models for neoantigen selection.BigGo FinancetrialOncodailyarXiv Commercial validation has arrived; differentiation now hinges on execution details.

4new stories
ClinicaltodayNew

Neoantigen Vaccines in Pancreatic Cancer in the Window Prior to Surgery

Washington University School of Medicine is running a randomized Phase 1 trial (active, not recruiting) of optimized neoantigen synthetic long peptide (SLP) vaccines co-administered with poly-ICLC in pancreatic cancer patients following neoadjuvant chemotherapy. The two arms test sequencing directly: vaccination after surgery versus vaccination in the window prior to surgery, while the tumor is still in place. Patients whose vaccine was manufactured but who progress on chemo or cannot complete resection may still receive injections on study. For a tumor type where vaccine development is difficult, the window-versus-post-surgery randomization is a low-cost sequencing question with implications for how the whole field schedules dosing around resection.

clinicaltrials · today · Washington University School of Medicine

03

01
CommercialyesterdayNew

Moderna Stock Up 650% This Year as Personalized Cancer Vaccine Battle With Keytruda Patent Cliff Takes Shape - BigGo Finance

Moderna is the S&P 500's top performer of 2026, up roughly 650%, with the catalyst being intismeran — its personalized mRNA cancer vaccine developed with Merck — positioned against Keytruda's patent cliff. In the Phase 3 INTerpath-001 trial in resected stage IIB–IV melanoma, intismeran plus Keytruda cut the risk of recurrence or death by 42% versus Keytruda alone at a median follow-up of 24.6 months, and reduced the risk of distant spread or death by 38%. The market is now treating personalized neoantigen vaccines as a commercial franchise rather than a science project. For the broader field, this is the clearest evidence yet that Phase 3 neoantigen data converts directly into valuation.

news · yesterday · BigGo Finance
02
AI / MethodsyesterdayNew

MIT Develops Nanovaccine Platform for Personalized Cancer Immunotherapy - Oncodaily

An MIT Koch Institute team (lead author Shengnan Huang, senior author Angela Belcher) published an M13 bacteriophage nanovaccine platform in Advanced Healthcare Materials in which the number of tumor antigens displayed on the particle surface is precisely engineered. In mouse colorectal cancer models, the optimized antigen density generated stronger cancer-specific T-cell responses and significantly suppressed tumor growth. The result positions antigen density — how antigens are presented, not just which ones are selected — as an underexplored design lever for personalized vaccine developers.

news · yesterday · Oncodaily
03
AI / Methods3 days agoNew

Benchmarking Machine-Learning Classifiers for Neoantigen Immunogenicity Prediction and the Limits of SHAP Interpretability

A benchmark of sixty models — twelve supervised classifier families in five configurations, evaluated on the ITSNdb dataset of 199 experimentally validated neoantigens (129 immunogenic, 70 non-immunogenic) under a strict stratified cross-validation protocol — finds classical linear models lead the ranking, while gradient-boosted ensembles and neural networks bring no advantage. A combined SHAP and feature-ablation study, plus a shuffled-label control, shows SHAP attributions can fail on high-cardinality categorical features. For teams building neoantigen prioritization pipelines, the takeaway is that added model complexity may not buy accuracy, and feature attributions should be validated before they drive peptide selection.

arxiv · 3 days ago · Ramon Gonzalez